ArticlePloS one2013
Urinary metabolic biomarker and pathway study of hepatitis B virus infected patients based on UPLC-MS system.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Glutathione Attenuates Copper Levels and Alleviates Hepatic Injury in TX Mice.Biological trace element research · 2025Article
- Pharmacokinetics in Pharmacometabolomics: Towards Personalized Medication.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Metabolomics in viral hepatitis: advances and review.Frontiers in cellular and infection microbiology · 2023Review
- Metabolomics: The Stethoscope for the Twenty-First Century.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2021Review
- Dynamic Metabolomics Study of the Bile Acid Pathway During Perioperative Primary Hepatic Carcinoma Following Liver Transplantation.Annals of transplantation · 2020Article
- Article
- Article
- Article
- Article
- Dissecting Efficacy and Metabolic Characteristic Mechanism ofFrontiers in pharmacology · 2020Article
- Comparative metabolomics unveils molecular changes and metabolic networks of syringin against hepatitis B mice by untargeted mass spectrometry.RSC advances · 2019Article
- Article
- Article
- Metabolomics biotechnology, applications, and future trends: a systematic review.RSC advances · 2019Review
- Article
- Untargeted metabolomics using liquid chromatography coupled with mass spectrometry for rapid discovery of metabolite biomarkers to reveal therapeutic effects ofRSC advances · 2019Article
- Targeting regulation of tryptophan metabolism for colorectal cancer therapy: a systematic review.RSC advances · 2019Review
- Network pharmacology combined with functional metabolomics discover bile acid metabolism as a promising target for mirabilite against colorectal cancer.RSC advances · 2018Article
- Urinary Metabolomic Profiling in Chronic Hepatitis B Viral Infection Using Gas Chromatography/Mass SpectrometryAsian Pacific journal of cancer prevention : APJCP · 2018Article
- Robust Regression Analysis of GCMS Data Reveals Differential Rewiring of Metabolic Networks in Hepatitis B and C Patients.Metabolites · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) is the fatal consequence of chronic hepatitis, and lack of biomarkers has been a long standing bottleneck in the clinical diagnosis. Metabolomics concerns with comprehensive analysis of small molecules and provides a powerful approach to discover biomarkers in biological systems. Here, we present metabolomics analysis applying ultra-performance liquid chromatography/electrospray ionization quadruple time-of-flight mass spectrometry. (UPLC-Q-TOF-HDMS) to determine metabolite alterations in HBV patients. Most important permutations are elaborated using multivariate statistical analysis and network analysis that was used to select the metabolites for the noninvasive diagnosis of HBV. In this study, the total 11 urinary differential metabolites were identified and contributed to HBV progress involving several key metabolic pathways by using pathway analysis with MetPA, which are promising biomarker candidates for diagnostic research. More importantly, of 11 altered metabolites, 4 metabolite markers were effective for the diagnosis of human HBV, achieved a satisfactory accuracy, sensitivity and specificity, respectively. It demonstrates that metabolomics has the potential as a non-invasive tool to evaluate the potential of these metabolites in the early diagnosis of HBV patients. These findings may be promising to yield a valuable insight into the pathophysiology of HBV and to advance the approaches of diagnosis, treatment, and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.